[Efficacy of keppra in combined therapy in pharmacoresistant adult epilepsy patients].
There were analyzed efficacy of keppra (Levetiracetam) in combined therapy in 31 patients with pharmacoresistant partial epilepsy and in 2 cases with idiopathic generalized epilepsy. During the 4 months 48.4% experienced at least a 50% reduction in the frequency of partial-oncet seizures, 12.9% at least a 75% reduction, and 25.8% demonstrated a seizure free. The combined therapy was ineffective only in 12.9%. The authors emphasize a good tolerability of keppra. There was only one case with side-effect, that demand cancel of Levetiracetam. The results obtained reveal effectiveness of keppra using in epileptology, in particular, in pharmacoresistant epilepsy.
Karlov
V A
VA
Vlasov
P N
PN
D000328:Adult; D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D004828:Epilepsies, Partial / Q000188:drug therapy*; D004829:Epilepsy, Generalized / Q000188:drug therapy; D005260:Female; D006801:Humans; D000077287:Levetiracetam; D008297:Male; D008875:Middle Aged; D010889:Piracetam / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014635:Valproic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D014815:Vitamins / Q000008:administration & dosage / Q000627:therapeutic use*
D000927:Anticonvulsants; D014815:Vitamins; D000077287:Levetiracetam; D014635:Valproic Acid; D010889:Piracetam